Publications by authors named "Amarante F"
Article Synopsis
- Patients with heart failure (HF) are at an increased risk of hospital readmission and mortality, particularly following a recent worsening heart failure (WHF) event.
- The FINEARTS-HF trial investigated the impact of the drug finerenone on cardiovascular events in HF patients, focusing on their WHF history and timing of treatment initiation.
- Results showed that those treated with finerenone shortly after a WHF event (within 7 days) had a significantly reduced risk of cardiovascular issues compared to the placebo group, indicating timeliness of treatment may influence effectiveness.
Article Synopsis
- Steroidal mineralocorticoid receptor antagonists help patients with heart failure and reduced ejection fraction, but their effectiveness in those with mildly reduced or preserved ejection fraction is unclear, indicating a need for further research on finerenone.
- In a double-blind study, patients with heart failure (ejection fraction 40% or greater) were assigned to receive either finerenone or a placebo to assess its impact on heart failure events and cardiovascular death.
- Results showed that finerenone led to fewer worsening heart failure events and a lower overall rate of primary outcome events compared to placebo, although it also carried a higher risk of hyperkalemia.
Aims: To describe the baseline characteristics of participants in the FINEARTS-HF trial, contextualized with prior trials including patients with heart failure (HF) with mildly reduced and preserved ejection fraction (HFmrEF/HFpEF). The FINEARTS-HF trial is comparing the effects of the non-steroidal mineralocorticoid receptor antagonist finerenone with placebo in reducing cardiovascular death and total worsening HF events in patients with HFmrEF/HFpEF.
Methods And Results: Patients with symptomatic HF, left ventricular ejection fraction (LVEF) ≥40%, estimated glomerular filtration rate ≥ 25 ml/min/1.
Lean muscle mass in classic or ovulatory PCOS: association with central obesity and insulin resistance.
Exp Clin Endocrinol Diabetes
October 2012
This age-matched case-control study assessed total and segmental lean muscle mass in classic or ovulatory polycystic ovary syndrome (PCOS) patients and investigated whether lean mass is associated with hormone and metabolic features. Participants underwent anthropometric and clinical evaluation. Habitual physical activity was assessed with a digital pedometer, and body composition by dual-energy X-ray absorptiometry.
View Article and Find Full Text PDFWomen with primary ovarian insufficiency have lower bone mineral density.
Braz J Med Biol Res
January 2011
The aim of the present study was to assess the prevalence of osteoporosis in a sample of 32 patients with spontaneous primary ovarian insufficiency (POI) in comparison to reference groups of 25 pre- and 55 postmenopausal women. Hip (lumbar) and spinal bone mineral density (BMD) measurements were performed by dual-energy X-ray absorptiometry in the three groups. The median age of POI patients at the time of diagnosis was 35 years (interquartile range: 27-37 years).
View Article and Find Full Text PDF